These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

917 related items for PubMed ID: 31340702

  • 1. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T, Seong SJ, Lee SK, Kim BR, Ju W, Kim KH, Nam K, Sim JC, Kim TJ.
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [Abstract] [Full Text] [Related]

  • 2. Screening capacity and cost-effectiveness of the human papillomavirus test versus cervicography as an adjunctive test to Pap cytology to detect high-grade cervical dysplasia.
    Song T, Seong SJ, Lee SK, Kim BR, Ju W, Kim KH, Nam K, Sim JC, Kim TJ.
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():112-116. PubMed ID: 30682600
    [Abstract] [Full Text] [Related]

  • 3. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
    Kim JH, Kim IW, Kim YW, Park DC, Kim YW, Lee KH, Ahn TG, Han SJ, Ahn WS.
    Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
    [Abstract] [Full Text] [Related]

  • 4. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.
    Costa S, Sideri M, Syrjänen K, Terzano P, De Nuzzo M, De Simone P, Cristiani P, Finarelli AC, Bovicelli A, Zamparelli A, Bovicelli L.
    Acta Cytol; 2000 Apr; 44(3):310-8. PubMed ID: 10833984
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O, Blaga ML, Nygård M, Leinonen MK, Nicula F, Păiş R, Coza D, Cadariu PA, Melnic A, Andreassen T, Hashim D, Weiderpass E.
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [Abstract] [Full Text] [Related]

  • 6. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
    Syrjänen K, Naud P, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Hammes LS, Matos J, Gontijo R, Sarian L, Braganca J, Arlindo FC, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S.
    Anticancer Res; 2005 Mar; 25(5):3469-80. PubMed ID: 16101165
    [Abstract] [Full Text] [Related]

  • 7. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A.
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [Abstract] [Full Text] [Related]

  • 8. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
    Longatto-Filho A, Naud P, Derchain SF, Roteli-Martins C, Tatti S, Hammes LS, Sarian LO, Eržen M, Branca M, de Matos JC, Gontijo R, Maeda MY, Lima T, Costa S, Syrjänen S, Syrjänen K.
    Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
    [Abstract] [Full Text] [Related]

  • 9. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
    Zhou H, Mody RR, Luna E, Armylagos D, Xu J, Schwartz MR, Mody DR, Ge Y.
    Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.
    JAMA; 2002 Oct 09; 288(14):1749-57. PubMed ID: 12365959
    [Abstract] [Full Text] [Related]

  • 11. Human papilloma virus infection of uterine cervix and spectrum of cervical pathology in human immunodeficiency virus/AIDS.
    Jain BB, Adhikary T, Sadhukhan PC, Nandi A.
    J Cancer Res Ther; 2021 Oct 09; 17(6):1462-1467. PubMed ID: 34916378
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
    Bansal M, Zhao C.
    J Low Genit Tract Dis; 2011 Apr 09; 15(2):105-9. PubMed ID: 21317806
    [Abstract] [Full Text] [Related]

  • 13. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.
    Syrjänen K, Derchain S, Roteli-Martins C, Longatto-Filho A, Hammes LS, Sarian L, Latin American Screening Study Group.
    Acta Cytol; 2008 Apr 09; 52(6):641-53. PubMed ID: 19068666
    [Abstract] [Full Text] [Related]

  • 14. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL, Sneige N, Gong Y, Bevers TB.
    Cancer Cytopathol; 2017 Aug 09; 125(8):644-651. PubMed ID: 28498639
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.
    J Natl Cancer Inst; 2003 Jan 01; 95(1):46-52. PubMed ID: 12509400
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Primary and Triage Cervical Screening Diagnostic Value of Methods for the Detection of Cervical Dysplasia.
    Njue JK, Muturi M, Kamau L, Lwembe R.
    Biomed Res Int; 2022 Jan 01; 2022():1930102. PubMed ID: 36164451
    [Abstract] [Full Text] [Related]

  • 20. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.
    J Clin Virol; 2009 Nov 01; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.